The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the application of single-cell sequencing of peripheral blood (PB) tumor cells to predict progression from monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) to multiple myeloma (MM). This technique identifies cytogenetic abnormalities and offers a comprehensive assessment of circulating tumor cells that surpasses the limitations of a bone marrow biopsy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Janssen, Oncopeptides, Amgen, Novartis, GlaxoSmithKline, The Binding Site, Window Therapeutics, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Huron Consulting, Takeda, Aptitude Health, Bristol-Myers Squibb; Honoraria: AbbVie, 10x Genomics, Janssen, Novartis, GlaxoSmithKline, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Takeda, Vor Biopharma, Adaptive, Bristol-Myers Squibb; Research Funding: Novartis; Ended employment in the past 24 months: Vor Biopharma; Speakers Bureau: Vor Biopharma; Spouse is Chief Medical Officer and holds equity in the company: Disc Medicine.
